Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bisacodyl is a stimulant laxative used for the short-term treatment of constipation and to empty the bowels before surgery or certain medical procedures. It acts directly on the colon by stimulating sensory nerve endings in the intestinal mucosa to increase peristalsis and promote bowel movements. Bisacodyl is also used in managing neurogenic bowel dysfunction and as part of bowel preparation regimens prior to diagnostic procedures such as colonoscopy. Its mechanism involves direct activation of colonic macrophages leading to increased prostaglandin E2 (PGE2) secretion and reduced expression of aquaporin-3 (AQP3), resulting in enhanced water secretion into the colon[1][2][6]. Bisacodyl is a derivative of triphenylmethane and has been widely available since 1953[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bisacodyl.